SCI offers safe anticoagulant potentialA synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Highly relevant to anticoagulant development
We explored the effects of a synthetic heparin mimetic known as sulfated chiro-inositol (SCI) on blood clotting mechanisms. This innovative treatment aims to inhibit human factor XIa (FXIa), a key player in the clotting process, while minimizing bleeding risks typically associated with anticoagulants.
In our study, we synthesized SCI to engage FXIa specifically by targeting its heparin-binding sites. Through various blood coagulation assays and in vivo models, we observed that SCI effectively inhibited FXIa, leading to reduced clot formation without significant safety concerns. In particular, SCI demonstrated potent anticoagulant properties, matching the performance of existing treatments like enoxaparin but at a much lower dosage.
Importantly, our investigations revealed that SCI's effects could be reversed by common antidotes, which adds an important layer of safety. While we noted no major bleeding risks or toxicity in the studies, further research is needed to ensure SCI's efficacy across broader clinical scenarios. Overall, our findings highlight SCI as a promising candidate for safer anticoagulation therapies.
Read More